SCHEMBL2860417

SCHEMBL2860417

COc1c(NC(=O)OCc2ccccc2)ccc2c1c(-c1cc3ccccc3s1)nn2C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
TACR3 P29371 1/20 0.37
LCK P06239 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
LIMK1 P53667 1/20 0.36
LIMK2 P53671 1/20 0.36
TEK Q02763 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
TNIK Q9UKE5 2/20 0.36
MAOB P27338 1/20 0.36
PLAU P00749 1/20 0.36
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2865210 0.90 MAOB (0.36) FAAHMGLLNPC1RAB9ASMN1; SMN2
SCHEMBL2861173 0.85 SRC (0.43) FAAHMGLLTACR3LCKSRC
SCHEMBL2863186 0.78 PIK3CD (0.42) PLAUHDAC2JAK2JAK3
SCHEMBL2862864 0.75 JAK2 (0.38) PLAUMAPTJAK2JAK3MAPK1
SCHEMBL2867721 0.74 SRC (0.39) FAAHMGLLTACR3LCKSRC
SCHEMBL2861505 0.72 MAOB (0.48) FAAHMGLLNPC1RAB9ASMN1; SMN2
SCHEMBL2855702 0.71 CA12 (0.38) PLAUHDAC2JAK2JAK3
SCHEMBL2862953 0.71 MGLL (0.43) MGLLLCKSRCKDRLIMK1
SCHEMBL17084245 0.69 MAPK1 (0.46) FAAHMGLLTACR3NPC1RAB9A
SCHEMBL2864575 0.68 PIK3CD (0.42) PLAUHDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 FAAH 2073/4885MGLL 4654/4885TACR3 1537/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 FAAH 1094/4885MGLL 4782/4885TACR3 2033/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 FAAH 2073/4885MGLL 4654/4885TACR3 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.